Orion Oyj-Product Pipeline Review-2015

Orion Oyj-Product Pipeline Review-2015

  • Products Id :- GMDHC06962CDB
  • |
  • Pages: 50
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Orion Oyj-Product Pipeline Review-2015


Global Markets Direct's, 'Orion Oyj-Product Pipeline Review-2015', provides an overview of the Orion Oyj's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Orion Oyj's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of Orion Oyj including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Orion Oyj's human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Orion Oyj's pipeline products

Reasons To Buy

Evaluate Orion Oyj's strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Orion Oyj in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Orion Oyj's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Orion Oyj and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Orion Oyj

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Orion Oyj and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Orion Oyj Snapshot 6

Orion Oyj Overview 6

Key Information 6

Key Facts 6

Orion Oyj-Research and Development Overview 7

Key Therapeutic Areas 7

Orion Oyj-Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products-Monotherapy 11

Pipeline Products-Combination Treatment Modalities 12

Pipeline Products-Out-Licensed Products 13

Out-Licensed Products/Combination Treatment Modalities 14

Orion Oyj-Pipeline Products Glance 15

Orion Oyj-Late Stage Pipeline Products 15

Phase III Products/Combination Treatment Modalities 15

Orion Oyj-Clinical Stage Pipeline Products 16

Phase II Products/Combination Treatment Modalities 16

Phase I Products/Combination Treatment Modalities 17

Orion Oyj-Early Stage Pipeline Products 18

Preclinical Products/Combination Treatment Modalities 18

Discovery Products/Combination Treatment Modalities 19

Orion Oyj-Drug Profiles 20

(budesonide + formoterol fumarate) 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

(fluticasone propionate + salmeterol) 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

levosimendan 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

ODM-201 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

dexmedetomidine hydrochloride 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

ODM-204 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

ODM-104 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

ODM-106 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

ODM-203 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

ORM-10103 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

Small Molecules to Inhibit BET Bromodomain for Oncology 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

Small Molecules for Pain 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

Orion Oyj-Pipeline Analysis 34

Orion Oyj-Pipeline Products by Target 34

Orion Oyj-Pipeline Products by Route of Administration 35

Orion Oyj-Pipeline Products by Molecule Type 36

Orion Oyj-Pipeline Products by Mechanism of Action 37

Orion Oyj-Recent Pipeline Updates 38

Orion Oyj-Dormant Projects 42

Orion Oyj-Discontinued Pipeline Products 43

Discontinued Pipeline Product Profiles 43

deramciclane 43

nitecapone 43

ODM-102 43

ORM-10921 43

Orion Oyj-Company Statement 44

Orion Oyj-Locations And Subsidiaries 46

Head Office 46

Other Locations & Subsidiaries 46

Appendix 49

Methodology 49

Coverage 49

Secondary Research 49

Primary Research 49

Expert Panel Validation 49

Contact Us 49

Disclaimer 50

List of Tables

Orion Oyj, Key Information 6

Orion Oyj, Key Facts 6

Orion Oyj-Pipeline by Indication, 2015 9

Orion Oyj-Pipeline by Stage of Development, 2015 10

Orion Oyj-Monotherapy Products in Pipeline, 2015 11

Orion Oyj-Combination Treatment Modalities in Pipeline, 2015 12

Orion Oyj-Out-Licensed Products in Pipeline, 2015 13

Orion Oyj-Out-Licensed Products/ Combination Treatment Modalities, 2015 14

Orion Oyj-Phase III, 2015 15

Orion Oyj-Phase II, 2015 16

Orion Oyj-Phase I, 2015 17

Orion Oyj-Preclinical, 2015 18

Orion Oyj-Discovery, 2015 19

Orion Oyj-Pipeline by Target, 2015 34

Orion Oyj-Pipeline by Route of Administration, 2015 35

Orion Oyj-Pipeline by Molecule Type, 2015 36

Orion Oyj-Pipeline Products by Mechanism of Action, 2015 37

Orion Oyj-Recent Pipeline Updates, 2015 38

Orion Oyj-Dormant Developmental Projects,2015 42

Orion Oyj-Discontinued Pipeline Products, 2015 43

Orion Oyj, Other Locations 46

Orion Oyj, Subsidiaries 47

List of Figures

Orion Oyj-Pipeline by Top 10 Indication, 2015 8

Orion Oyj-Pipeline by Stage of Development, 2015 10

Orion Oyj-Monotherapy Products in Pipeline, 2015 11

Orion Oyj-Out-Licensed Products in Pipeline, 2015 13

Orion Oyj-Pipeline by Top 10 Target, 2015 34

Orion Oyj-Pipeline by Top 10 Route of Administration, 2015 35

Orion Oyj-Pipeline by Top 10 Molecule Type, 2015 36

Orion Oyj-Pipeline Products by Top 10 Mechanism of Action, 2015 37

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com

Current R&D Portfolio of Orion Oyj; Orion Oyj - Key Therapeutics; Orion Oyj - Pipeline Overview and Promising Molecules; Orion Oyj - News; Orion Oyj - Latest Updates; Orion Oyj - Pipeline; Orion Oyj - Discontinued/Dormant Projects

select a license
Single User License
USD 1500 INR 108555
Site License
USD 3000 INR 217110
Corporate User License
USD 4500 INR 325665



I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@] kenresearch.com